From 31 January 2022, it is a mandatory requirement for all patients who want to access face to face medical and allied health services to show proof of vaccination (double dosed) AND proof of identification. If patients are unvaccinated or only had one vaccination, they can still access medical and allied health services through tele-health and video-link. Be kind…our staff don’t make the rules. Help us follow the rules and keep WA safe.


Fresh Start has been involved in a number of clinical studies, which have helped to shape the evidence base  of treatments we provide at our clinic and improves patient outcomes. Over the years, we have published numerous studies in peer-reviewed journals.

Supporting and continuing research at Fresh Start is an important aspect of what we do and we will continue to support and train our future researchers.

Research that has been conducted at Fresh Start

Changes in hospital outpatient events and costs following implant naltrexone treatment for problematic alcohol use https://journals.sagepub.com/doi/full/10.1177/0269881114536791

Main finding: Costs associated with hospital and emergency department admissions post-treatment were significantly reduced compared to pre-treatment.

A retrospective assessment of the use of naltrexone implants for the treatment of problematic amphetamine use https://onlinelibrary.wiley.com/doi/full/10.1111/j.1521-0391.2013.00320.x

Main finding: Treatment was associated with abstinence from amphetamines for at least one months in 65.9% of participants. 48.3% reported abstinence at six months.

A double-blind randomised crossover trial of low-dose flumazenil for benzodiazepine withdrawal: A proof of concept https://www.sciencedirect.com/science/article/pii/S0376871622002381

Main finding: benzodiazepine use in was significantly reduced in high-dose benzodiazepine users compared to placebo.

Outcomes of patients treated with low-dose flumazenil for benzodiazepine detoxification: A description of 26 participants https://www.sciencedirect.com/science/article/pii/S037687162200254X

Main finding: Abstinence rate from benzodiazepines at three months was between 46.2% and 61.5%.

Pharmacological uses of flumazenil in benzodiazepine use disorders: A systematic review of limited data https://journals.sagepub.com/doi/full/10.1177/0269881120981390

Main finding: The treatment is promising for benzodiazepine withdrawal; however, more randomised control trials are required before a definitive recommendation can be made around its use.

A theory of the anxiolytic action of flumazenil in anxiety disorders https://journals.sagepub.com/doi/full/10.1177/02698811221082466

Main finding: Chronic stress may lead to dysfunction receptors, which are implicated in anxiety. Treatment may reset these receptors and have an anti-anxiety effect.

The role of flumazenil in the treatment of benzodiazepine dependence: physiological and psychological profiles https://journals.sagepub.com/doi/abs/10.1177/0269881108100322

Main finding: treatment appears to be safe and effective, resulting in lesser severity withdrawal symptoms that other cessation methods currently available.

Improving clinical outcomes in treated heroin dependence: Randomised, control trial of oral or implant naltrexone https://jamanetwork.com/journals/jamapsychiatry/article-abstract/210360

Main finding: Sustained release treatment reduced relapse to regular opioid use compared to the oral preparation and was not associated with any major adverse events.

Blood naltrexone and 6-β-naltrexol levels following naltrexone implant: comparing two naltrexone implants https://onlinelibrary.wiley.com/doi/abs/10.1080/13556210410001674103

Main finding: One of the preparations was able to provide therapeutic levels of the drug for 6.3 months compared to only 3 months.

Hyperbolic dose reduction of escitalopram mitigates withdrawal syndrome: A case report https://www.sciencedirect.com/science/article/pii/S2773021222000098

Main finding: In this case study, a patient who was sensitive to withdrawal from “antidepressants” did not experience a withdrawal syndrome when reducing their dose in a different way to usual dose reduction strategies.

We are currently working on writing and publishing several articles related to benzodiazepine withdrawal and anxiety. A brief description of these is below:

  1. An analysis of data from a randomised control crossover trial to assess whether treatment has an effect of anxiety levels during benzodiazepine withdrawal (manuscript in preparation).
  2. Data from a series of participants receiving treatment for generalised anxiety disorder, some with treatment resistance, and the short-term outcomes up to one-month (submitted for publication).
  3. The long-term outcomes, up to one year, of participants receiving treatment for generalised anxiety disorder (manuscript in preparation).